The X‐ray analyses of (η3‐allyl){4‐benzyl‐2‐[2‐(diphenylphosphino‐κP)phenyl]‐4,5‐dihydro‐4‐4‐methyloxazole‐κN}palladium(II) hexafluorophosphate (5) and the analogous [Pd(η3‐1,3‐diphenylallyl)] complex 6 are presented. A comparison with the (η3‐allyl)‐ and (η‐1,3‐diphenylallyl)palladium complexes 2 and 3, respectively, containing the 4‐monosubstituted 4,5‐dihydro‐2‐(phosphinoaryl)oxazole ligand 1a reveals important structural differences (Fig. 3). 1H‐NMR Spectroscopic investigation confirm that the 4,4‐disubstituted 4,5‐dihydro‐2‐(phosphinoaryl)oxazole ligand 4 of 5 and 6 shows the same conformation in solution as in the solid state (Table 2). The application of ligand (S)‐4 in the Pd‐catalyzed allylic substitution demonstrates a configurational relationship between the orientation of the allyl ligand in the intermediate (cf. complex 6) and the absolute configuration of the allylic‐substitution product (Table 3).
No takes yet. Share an insight, caveat, or question.
Schaffner et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: